An Open-Label, Sequential Treatment Study to Assess the Single and Multiple Dose Pharmacokinetics of a New Tapentadol Prolonged-Release 250 mg Formulation in Healthy Subjects

Trial Profile

An Open-Label, Sequential Treatment Study to Assess the Single and Multiple Dose Pharmacokinetics of a New Tapentadol Prolonged-Release 250 mg Formulation in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2013

At a glance

  • Drugs Tapentadol (Primary)
  • Indications Back pain; Cancer pain; Diabetic neuropathies; Musculoskeletal pain; Neuropathic pain; Pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 19 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top